Zusammenfassung
Die Bedeutung und Relevanz der Dosis bei der Therapie mit Zytostatika ist allgemein anerkannt [1]. Präklinische Modelle sowohl hämatologischer als auch solider Tumore lassen eine verstärkte Abtötung von Tumorzellen erkennen, wenn maligne Zellpopulationen zytotoxischen Wirkstoffen in höheren Konzentrationen ausgesetzt werden [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Frei III E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585–94.
Schabel Jr FM, Griswold Jr DP, Corbett TH, Laster Jr WR. Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Ther. 1983;20:283–305.
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371–82.
Tan MC, Al MF, Gao F, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg. 2009;198:520–5.
Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92:2585–91.
Bessette AR, Benedetti-Panici PL, Boman K, et al. Randomised trial comparing primary debulking surgery (PDS) with neoadjuvant chemotherapy (NACT) followed by interval debulking (IDS) in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. IGCS 12th biennial meeting proceedings, Bangkok; 25–28 Oct 2008.
Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162–70.
Hryniuk W. Will increases in dose intensity improve outcome: pro. Am J Med. 1995; 99:69S–70.
McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589–99.
Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998;16:2426–34.
Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17–26.
Grenman S, Wiklund T, Jalkanen J, et al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer. 2006;42:2196–9.
Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002;20:743–50.
Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–8.
Markman M. Regional antineoplastic drug delivery in the management of malignant disease. Baltimore: The Johns Hopkins University Press; 1991.
Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988–94.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Markman, M. (2013). Das Dosis-Wirkung-Prinzip in Verbindung mit der Zufuhr von Antineoplastika. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-35014-6_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35013-9
Online ISBN: 978-3-642-35014-6
eBook Packages: Medicine (German Language)